ScandiDos AB
ScandiDos AB (publ), together with its subsidiaries, provides measurement phantoms and software solutions for the quality assurance and validation of dynamic and modulated treatments adopted in clinics in the United States, Europe, Asia, and internationally. The company offers Delta4 products comprising Delta4 Phantom+, Delta4Phantom+MR, Delta4 HexaMotion, Delta4Insight, Delta4DVH Anatomy, Delta4… Read more
ScandiDos AB (SDOS) - Net Assets
Latest net assets as of October 2025: Skr43.19 Million SEK
Based on the latest financial reports, ScandiDos AB (SDOS) has net assets worth Skr43.19 Million SEK as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr68.29 Million) and total liabilities (Skr25.09 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr43.19 Million |
| % of Total Assets | 63.25% |
| Annual Growth Rate | 9.87% |
| 5-Year Change | -0.44% |
| 10-Year Change | 40.57% |
| Growth Volatility | 79.93 |
ScandiDos AB - Net Assets Trend (2011–2025)
This chart illustrates how ScandiDos AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ScandiDos AB (2011–2025)
The table below shows the annual net assets of ScandiDos AB from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-04-30 | Skr44.98 Million | +1.56% |
| 2024-04-30 | Skr44.29 Million | +6.32% |
| 2023-04-30 | Skr41.65 Million | +11.98% |
| 2022-04-30 | Skr37.20 Million | -17.67% |
| 2021-04-30 | Skr45.18 Million | -2.33% |
| 2020-04-30 | Skr46.26 Million | +61.64% |
| 2019-04-30 | Skr28.62 Million | -38.56% |
| 2018-04-30 | Skr46.58 Million | +5.85% |
| 2017-04-30 | Skr44.00 Million | +37.51% |
| 2016-04-30 | Skr32.00 Million | +26.26% |
| 2015-04-30 | Skr25.34 Million | -37.40% |
| 2014-04-30 | Skr40.48 Million | +296.54% |
| 2013-04-30 | Skr10.21 Million | -17.11% |
| 2012-04-30 | Skr12.32 Million | +2.23% |
| 2011-04-30 | Skr12.05 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ScandiDos AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 51202.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (April 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr2.85 Million | 6.34% |
| Other Components | Skr206.17 Million | 458.35% |
| Total Equity | Skr44.98 Million | 100.00% |
ScandiDos AB Competitors by Market Cap
The table below lists competitors of ScandiDos AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Izoblok
WAR:IZB
|
$2.18 Million |
|
Expion360 Inc
NASDAQ:XPON
|
$2.18 Million |
|
GreenPower Motor Company Inc
NASDAQ:GP
|
$2.18 Million |
|
Sescom SA
WAR:SES
|
$2.18 Million |
|
ARIP Public Company Limited
BK:ARIP
|
$2.18 Million |
|
LCC Infotech Limited
NSE:LCCINFOTEC
|
$2.18 Million |
|
Ambertech Ltd
AU:AMO
|
$2.18 Million |
|
Sin-Kung Logistics Berhad
KLSE:0305
|
$2.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ScandiDos AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 44,287,000 to 44,980,000, a change of 693,000 (1.6%).
- Net loss of 14,647,000 reduced equity.
- Share repurchases of 18,244,000 reduced equity.
- New share issuances of 18,244,000 increased equity.
- Other comprehensive income decreased equity by 42,199,000.
- Other factors increased equity by 57,539,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-14.65 Million | -32.56% |
| Share Repurchases | Skr18.24 Million | -40.56% |
| Share Issuances | Skr18.24 Million | +40.56% |
| Other Comprehensive Income | Skr-42.20 Million | -93.82% |
| Other Changes | Skr57.54 Million | +127.92% |
| Total Change | Skr- | 1.56% |
Book Value vs Market Value Analysis
This analysis compares ScandiDos AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.04x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.18x to 1.04x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-04-30 | Skr5.57 | Skr1.03 | x |
| 2012-04-30 | Skr5.69 | Skr1.03 | x |
| 2013-04-30 | Skr4.72 | Skr1.03 | x |
| 2014-04-30 | Skr2.78 | Skr1.03 | x |
| 2015-04-30 | Skr1.86 | Skr1.03 | x |
| 2016-04-30 | Skr1.68 | Skr1.03 | x |
| 2017-04-30 | Skr1.66 | Skr1.03 | x |
| 2018-04-30 | Skr1.54 | Skr1.03 | x |
| 2019-04-30 | Skr0.99 | Skr1.03 | x |
| 2020-04-30 | Skr1.12 | Skr1.03 | x |
| 2021-04-30 | Skr1.09 | Skr1.03 | x |
| 2022-04-30 | Skr0.90 | Skr1.03 | x |
| 2023-04-30 | Skr0.91 | Skr1.03 | x |
| 2024-04-30 | Skr0.97 | Skr1.03 | x |
| 2025-04-30 | Skr0.99 | Skr1.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ScandiDos AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -32.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -24.24%
- • Asset Turnover: 0.82x
- • Equity Multiplier: 1.63x
- Recent ROE (-32.56%) is below the historical average (-25.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 2.66% | 1.11% | 1.49x | 1.62x | Skr-883.80K |
| 2012 | 1.84% | 0.63% | 1.47x | 1.98x | Skr-1.00 Million |
| 2013 | -20.50% | -5.25% | 1.35x | 2.88x | Skr-3.11 Million |
| 2014 | -10.37% | -10.85% | 0.72x | 1.33x | Skr-8.25 Million |
| 2015 | -57.94% | -44.60% | 0.76x | 1.71x | Skr-17.22 Million |
| 2016 | -44.51% | -42.42% | 0.58x | 1.80x | Skr-17.44 Million |
| 2017 | -29.90% | -27.75% | 0.75x | 1.44x | Skr-17.56 Million |
| 2018 | -24.83% | -22.87% | 0.76x | 1.42x | Skr-16.22 Million |
| 2019 | -62.06% | -36.38% | 0.71x | 2.42x | Skr-20.62 Million |
| 2020 | -28.39% | -22.93% | 0.81x | 1.53x | Skr-17.76 Million |
| 2021 | -3.10% | -2.33% | 0.78x | 1.71x | Skr-5.92 Million |
| 2022 | -19.73% | -12.72% | 0.87x | 1.78x | Skr-11.06 Million |
| 2023 | -21.89% | -14.82% | 0.85x | 1.74x | Skr-13.28 Million |
| 2024 | -33.07% | -24.24% | 0.74x | 1.84x | Skr-19.08 Million |
| 2025 | -32.56% | -24.24% | 0.82x | 1.63x | Skr-19.14 Million |
Industry Comparison
This section compares ScandiDos AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $75,200,026
- Average return on equity (ROE) among peers: -74.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ScandiDos AB (SDOS) | Skr43.19 Million | 2.66% | 0.58x | $2.18 Million |
| Acarix A/S (ACARIX) | $76.60 Million | -60.65% | 0.08x | $28.86 Million |
| Arcoma AB (ARCOMA) | $12.52 Million | -92.85% | 4.66x | $8.93 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $353.18 Million | -39.18% | 0.87x | $19.20 Million |
| CellaVision AB (CEVI) | $20.07 Million | 13.08% | 1.20x | $262.59 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $65.69 Million | -72.50% | 0.20x | $13.78 Million |
| Chordate Medical Holding AB (CMH) | $38.95 Million | -55.88% | 0.13x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $93.64 Million | 22.63% | 0.57x | $56.67 Million |
| Duearity AB (DEAR) | $-2.39 Million | 0.00% | 0.00x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $41.40 Million | -170.53% | 0.39x | $5.40 Million |